Spondyloarthritis & psoriatic arthritis
Clinical outcomes in psoriatic arthritis patients with rheumatoid factor positivity
Authors' conclusion
RF was observed in 16.1% of the cohort, with 5.1% being positive at baseline. RF positivity was associated with lower odds for achievement of MDA and with bDMARD discontinuation.
Study context
- Population
- Patients with psoriatic arthritis (PsA) enrolled after 1996 in a large PsA cohort
- Participants
- 1,074 patients
- Exposure
- Rheumatoid factors (RF) positivity vs RF negativity
- RF positivityn = 173
- Outcome
- Frequency and impact of RF positivity on clinical outcomes (MDA achievement, MDA components) and bDMARD discontinuation
Methodological detailsgeneralized estimating equations (univariable and multivariable)
- Generalized estimating equations (univariable and multivariable)
Main finding
As reported in the abstract
Frequency of RF positivity
RF positive
16.1%
173 events
- RF positive at baseline: 55
- 5.1%
Observational data: associations, not effects.
Further findings
Achievement of minimal disease activity (MDA)
| OR (95% CI) | ||
|---|---|---|
| RF positivityMV · multivariable generalized estimating equations | 0.53 (0.37–0.77) | |
| 0.20.5125Odds ratio (log scale) |
bDMARD discontinuation
| OR (95% CI) | ||
|---|---|---|
| RF positivityMV; ever RF positivity · independent of joint and skin disease activity | 2.65 (1.34–5.24) | |
| New RF positivityMV · independent of joint and skin disease activity | 2.78 (1.57–4.92) | |
| 0.20.5125Odds ratio (log scale) |
Achievement of MDA
- Driven by worse patient pain, patient global and physical function, particularly in the bDMARD subgroup; associations persisted in the bDMARD subgroup when restricted to new RF positivity
Original publication
Clinical outcomes in psoriatic arthritis patients with rheumatoid factor positivity. Rheumatology (Oxford). Published 25 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →